drugset / Trial / NCT05921370

Silodosin in Retrograde Intrarenal Surgery

NCT05921370

Phase 3 Completed 60 enrolled Ain Shams University
RandomizedParallel-groupSingle-blindTreatment

Summary

Selective alpha-blockers have been used for the treatment of ureteric stones as medical expulsive therapy (MET). Recently they have been successfully used in passive ureteric dilatation before semirigid ureteroscopy. This study enables us to know the role of silodosin in ureteric dilatation to facilitate ureteral access sheath placement in Retrograde Intrarenal Surgery with flexible ureteroscopy.

Timeline

Start
2023-04-04
Primary completion
2023-07-01
Completion
2023-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Silodosin Unknown 8 mg

Indications